Immuno-Oncology

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers, such as circulating tumor DNA and KRAS mutations, in guiding treatment decisions.

Although rare, clinicians should be familiar with the symptoms and management of immune checkpoint inhibitor (ICI)–related cardiovascular adverse effects or myocarditis.

In this review, authors explain the supply chain issues of getting a life-saving treatment "vein to vein."

United Urology Group, with 4 practices in Maryland, Colorado, Arizona, and Tennessee, has agreed to be acquired by OneOncology, which last year was acquired by TPG and AmeriSourceBergen in a $2.1 billion transaction.

The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found.

Part of the Institute for Value-Based Medicine series, the June 20, 2024, event was presented with Banner MD Anderson in Phoenix, Arizona.

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers.

Researchers from the University of Manchester sought to understand whether the season of administration of immunotherapy affected outcomes.

Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

The FDA has approved durvalumab combined with carboplatin and paclitaxel, followed by single-agent durvalumab.

Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.